Fundraise

Qiming backs AI-native biotech CataX AI in sole seed bet

What's the deal? CataX AI, a Shanghai-based AI-native biotech, has raised a seed round backed solely by Qiming Venture Partners. Founded in July 2026, the company uses AI agents to speed up the early clinical development of new drugs rather than chasing targets and molecules.

Why now? Qiming partner Chen Kan, co-head of its healthcare innovation practice, argues AI is now mature in target discovery and molecular design, so the industry bottleneck has moved downstream. Early drug discovery accounts for only about 20% of a new drug's cost and time; the remaining 80% sits in clinical development, which can run a decade and cost billions of dollars.

Who's behind it? Founder Wang Zilong holds an eight-year clinical medicine degree and an oncology doctorate from Fudan University. He later served as chief technology officer and chief medical officer at an AI medical company, made the Forbes 30 Under 30 list, and worked as a senior researcher at Microsoft Research Asia.

What's the endgame? CataX AI targets preclinical and early clinical pipelines, acquiring rights through licensing or co-development and pushing assets to human proof-of-concept before seeking to out-license. It runs a "Clinical-of-One" model, where a single clinical lead coordinates agents and outside experts; agents handle research, drafting, and data work, while people make key decisions.

Qiming, one of China's earliest AI-drug investors with prior bets including Insilico Medicine, incubated the company alongside Wang. It introduced co-founder and chief development officer Jiang Zhemin, who spent more than a decade in clinical operations at firms including TigermedDealroom has a profile for this one. Try Dealroom → and BeiGeneDealroom has a profile for this one. Try Dealroom →.

What could go wrong? Wang concedes the model is hard to scale: pipeline leads need both deep clinical knowledge and AI fluency, and such people are scarce. "I have no way to clone 10 of myself," he said. His proposed fix is to capture "organisational experience" — expert feedback and decision trails — in one system so new hires can draw on it.

The signal: The round lands as China's innovative drugs push globally, with Chinese preclinical candidates making up 44% of the world's output in recent years. Chen notes overseas pharma interest in Chinese assets has shifted from price to quality, leaving promising early projects short of capital — a gap that AI-native biotechs aim to fill.

Read more: 36kr.com

Image credit: "Naval Medical Research Center (NMRC) Clinical Trials Center (CTC) Conducts Melatonin and Vaccine Response Immunity and Chronobiology Study 221108-N-UM734-1064" by NavyMedicine, public domain (Public Domain Mark 1.0)

More top stories